COVID-19 vaccine hesitancy among Israeli adults before and after vaccines' availability: A cross-sectional national survey.
COVID-19
Israel
SARS-CoV-2
Vaccine hesitancy
Vaccine uptake
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
12 10 2022
12 10 2022
Historique:
received:
07
04
2022
revised:
17
07
2022
accepted:
03
08
2022
pubmed:
23
9
2022
medline:
12
10
2022
entrez:
22
9
2022
Statut:
ppublish
Résumé
Vaccine hesitancy (VH) is a major health threat to the efforts to tackle COVID-19 morbidity and mortality. This study's objectives were to assess COVID-19VH before and after vaccines' availability and to analyze the associations between COVID-19VH and participants' characteristics. A national cross-sectional telephone interview survey among Israeli adults aged 21 and older was conducted from September 2020 through May 2021. Attitudes towards COVID-19 vaccines were assessed pre/post vaccines' availability. Multivariate logistic regression analyses were used to identify associations between demographic and health-related characteristics and COVID-19 VH. Most study participants (72.0 % of 2,998) were willing to be vaccinated against COVID-19 across the survey period. The COVID-19 VH declined significantly from 45.6 % pre-vaccine availability to 16.3 % post-vaccine availability (P < 0.001). The multivariable analysis demonstrated that post-vaccine availability, COVID-19 VH was associated with younger age, Arab ethnicity, higher level of religiosity, lower education, past diagnosis of COVID-19, and influenza VH. The main reasons for VH after the vaccine availability included insufficient data on the vaccine (37.4 %) and fear of the vaccine's side effects (33.8 %). Despite the significant decrease in COVID-19 VH following vaccine availability, 16.3% of the population still refuses to get vaccinated. As Israel may face additional waves of the COVID-19 pandemic and booster vaccinations, multimedia vaccine promotions targeting the above-mentioned hesitant populations and their reasons for VH are urgently needed.
Identifiants
pubmed: 36137905
pii: S0264-410X(22)01078-7
doi: 10.1016/j.vaccine.2022.08.070
pmc: PMC9472961
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Influenza Vaccines
0
Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6271-6276Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Hum Vaccin Immunother. 2021 Jun 3;17(6):1612-1621
pubmed: 33242386
Brain Behav Immun. 2021 May;94:41-50
pubmed: 33713824
Vaccines (Basel). 2020 Oct 03;8(4):
pubmed: 33022917
Isr J Health Policy Res. 2021 Mar 19;10(1):26
pubmed: 33741063
Nat Med. 2021 Feb;27(2):225-228
pubmed: 33082575
BMC Public Health. 2021 Apr 26;21(1):804
pubmed: 33902501
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
Vaccine. 2014 Apr 17;32(19):2150-9
pubmed: 24598724
JAMA Netw Open. 2020 Oct 1;3(10):e2025594
pubmed: 33079199
Lancet Public Health. 2021 Apr;6(4):e210-e221
pubmed: 33556325
Lancet Reg Health Eur. 2021 Aug;7:100130
pubmed: 34109321
Nat Rev Immunol. 2021 Apr;21(4):198-199
pubmed: 33712744
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Prev Med. 2021 Dec;153:106763
pubmed: 34352308
Nat Med. 2021 Jun;27(6):1055-1061
pubmed: 33875890
J Health Commun. 2020 Oct 2;25(10):816-818
pubmed: 33719884
Vaccines (Basel). 2021 Feb 16;9(2):
pubmed: 33669441
Vaccines (Basel). 2020 Aug 27;8(3):
pubmed: 32867224
J Community Health. 2021 Apr;46(2):270-277
pubmed: 33389421
Clin Microbiol Infect. 2021 Oct;27(10):1502-1506
pubmed: 34111591
Isr J Health Policy Res. 2021 Jan 26;10(1):6
pubmed: 33499905